For more information on becoming an event/media partner, please contact Jon Liong at firstname.lastname@example.org.
BayHelix Group is a non-profit, invitation-only organization of business leaders of Chinese heritage that fosters the growth of the life sciences and healthcare industry around the Pacific Rim and beyond. Founded in 2001, BayHelix has grown to over 300 members throughout the U.S., Canada, and Greater China. The membership base covers virtually all of the world’s top pharmaceutical and biopharmaceutical companies, as well as leading services and investment firms. Over one third of the members are senior executives, over 80% have PhDs in the life sciences, and nearly half have MBAs from the leading business schools in U.S.
Founded by industry-recognized editors, RNDer and PharmaDJ are the leading publications providing value-added analysis for pharmaceutical and biotechnology companies doing business in China. With a mission to facilitate drug R&D and regulatory science in China, we talk to regulators and key opinion leaders from industry to piece together the China market puzzle for our readers.
ZHANGJIANG LIFE SCIENCE CLUSTER
Zhangjiang biotech & pharmaceutical industrial base (Zhangjiang Life Science Cluster) is founded by Ministry of Science and Technology, Ministry of Health, CFDA, CAS, CAE and the Shanghai Municipal Government. In 1 square kilometer area, it has gathered 450+ biotech and pharmaceutical innovation start-ups, 40+ CROs and 70+ scientific research institutes, technology centers, universities and service platforms, including nearly 40,000 employees.
Over the past 25 years, Zhangjiang has focused on creating an innovative Eco-system, which includes over 80% small and medium-sized biotech/pharmaceutical companies and entrepreneurs, totally 10% headquarters or R&D centers of multinational"big-pharma"/"Top 100 of Chinese pharma", and the professional service providers, VCs, universities, research institutes and SHFDA. At the same time, Zhangjiang has also established the complete industrial system covering research, development and CMO facility under MAH policy.
In 2016, 10+ biotech and pharmaceutical start-ups have got investment of over 1 Billion(USD) totally in Zhangjiang. 2017 Q1, over 50% of the drugs which were approved to clinical trials by CFDA were applied by companies in Zhangjiang.
Biodiscover (www.biodiscover.com) is a newly media portal to explore the value of biosciences, and committed to disseminate the forefront of biotechnology and successful business model in the field of life sciences. Biodiscover.com has more than 13,000 registered users so far. Additionally, our website gains over 2000,000 page views per month.
Our website introduces the most advanced and dynamic bioinformatics technology in the field of life sciences, providing prospective, in-depth research information and technical topics for biologists in china; providing the latest bioindustry dynamics and reports for enterprises; providing a interaction platform for biological enterprises and individuals; integrating the latest exhibitions, conferences and technical seminars of biopharmaceutical etc.
Since its founding in January, 2007, ChinaBio® LLC has rapidly launched a number of initiatives accelerating the globalization of China's life science industry. ChinaBio has helped China companies raise nearly $400 million and global life science companies identify over 400 licensing and acquisition opportunities in China.
- Conferences: ChinaBio organizes the premier life science investment and partnering conferences in China, having attracted over 4,000 attendees.
- Consulting: ChinaBio works with global life science companies and China entrepreneurs to define and execute a successful global strategy.
- Transactions: ChinaBio Capital helps companies secure partnerships and acquisitions and access private and government funding in China.
- Publishing: ChinaBio Today is the most widely read online and email newsletter on China's life science industry.
DXY is the top connector and leading digital service provider in the healthcare industry of China.For the past 16 years, DXY has built the largest online forum for physicians, launched a series of mobile applications and opened its wholly-owned clinics. DXY’s services include professional information s-haring platform, comprehensive data accumulation and management, high-quality medical service-s, which connect Patient, Physician, Pharma, and Payer. By the end of 2015, DXY has tens of millio-ns of users in China, more than 5 million registered members, including 2 million physicians and 1.37 million licensed physicians.DXY has opened DXClinics in Hangzhou and Fuzhou, with plans for a continual expansion in the near future. （DXY is short for lilac garden in Chinese Pinyin.）
Founded in Shanghai in 2002, GBI has built a diverse portfolio of market intelligence solutions for pharmaceutical and device companies and other service providers. Focused on China and the Latin American markets, GBI’s value-added industry information, news, and data services power individuals and organizations’ decision-making and enable more effective communication. As a trusted source of information, GBI has established long-term relationships with both multinational players and local firms, and continues to drive forward the health care industry.
GBI has offices in Shanghai, Beijing, and Washington D.C.
Healthcare Drinks China
Healthcare Drinks (HCD) is a platform with a popular series of after work networking events for the medical industry organized by leading healthcare executives. It was started in Shanghai and there are active chapters in Beijing, Boston, Changsha, Guangzhou, Hong Kong, Kunming, Melbourne, Singapore, San Francisco, Shenzhen and Taipei. (www.healthcaredrinks.com)